1. Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US multi-society task force on colorectal cancer. Gastroenterology. 2012; 143:844–857.
Article
2. Bressler B, Paszat LF, Chen Z, Rothwell DM, Vinden C, Rabeneck L. Rates of new or missed colorectal cancers after colonoscopy and their risk factors: a population-based analysis. Gastroenterology. 2007; 132:96–102.
Article
3. Sanduleanu S, le Clercq CM, Dekker E, et al. Definition and taxonomy of interval colorectal cancers: a proposal for standardising nomenclature. Gut. 2015; 64:1257–1267.
Article
4. Baxter NN, Sutradhar R, Forbes SS, Paszat LF, Saskin R, Rabeneck L. Analysis of administrative data finds endoscopist quality measures associated with postcolonoscopy colorectal cancer. Gastroenterology. 2011; 140:65–72.
Article
5. Rutter MD, Beintaris I, Valori R, et al. World endoscopy organization consensus statements on post-colonoscopy and postimaging colorectal cancer. Gastroenterology. 2018; 155:909–925.e3.
6. Cha JM, Kim HS, Kwak MS, et al. Features of postcolonoscopy colorectal cancer and survival times of patients in Korea. Clin Gastroenterol Hepatol. 2019; 17:786–788.
Article
7. Cha JM, Kwak MS, Kim HS, et al. Real-world national colonoscopy volume in Korea: a nationwide population-based study over 12 years. Gut Liver. 2019; 09. 19. [Epub ahead of print].
Article
8. Choi KS, Jun JK, Park EC, et al. Performance of different gastric cancer screening methods in Korea: a population-based study. PLoS One. 2012; 7:e50041.
Article
9. Jun JK, Choi KS, Lee HY, et al. Effectiveness of the Korean national cancer screening program in reducing gastric cancer mortality. Gastroenterology. 2017; 152:1319–1328.e7.
Article
10. Choi KS, Jun JK, Suh M, et al. Effect of endoscopy screening on stage at gastric cancer diagnosis: results of the national cancer screening programme in Korea. Br J Cancer. 2015; 112:608–612.
Article
11. Park SH, Kim YJ, Rhee KH, et al. A 30-year trend analysis in the epidemiology of inflammatory bowel disease in the Songpa-Kangdong district of Seoul, Korea in 1986-2015. J Crohns Colitis. 2019; 13:1410–1417.
Article
12. Benchimol EI, Manuel DG, Guttmann A, et al. Changing age demographics of inflammatory bowel disease in Ontario, Canada: a population-based cohort study of epidemiology trends. Inflamm Bowel Dis. 2014; 20:1761–1769.
13. Melesse DY, Lix LM, Nugent Z, et al. Estimates of disease course in inflammatory bowel disease using administrative data: a population-level study. J Crohns Colitis. 2017; 11:562–570.
Article
14. Coward S, Clement F, Benchimol EI, et al. Past and future burden of inflammatory bowel diseases based on modeling of population-based data. Gastroenterology. 2019; 156:1345–1353.e4.
Article
15. Kim HJ, Hann HJ, Hong SN, et al. Incidence and natural course of inflammatory bowel disease in Korea, 2006–2012: a nationwide population-based study. Inflamm Bowel Dis. 2015; 21:623–630.
16. Jung YS, Han M, Kim WH, Park S, Cheon JH. Incidence and clinical outcomes of inflammatory bowel disease in South Korea, 2011-2014: a nationwide population-based study. Dig Dis Sci. 2017; 62:2102–2112.
Article
17. Bae JM, Lee HH, Lee BI, et al. Incidence of psoriasiform diseases secondary to tumour necrosis factor antagonists in patients with inflammatory bowel disease: a nationwide population-based cohort study. Aliment Pharmacol Ther. 2018; 48:196–205.
Article
18. Chang K, Lee HS, Kim YJ, et al. Increased risk of herpes zoster infection in patients with inflammatory bowel diseases in Korea. Clin Gastroenterol Hepatol. 2018; 16:1928–1936.e2.
Article
19. Lee CK, Ha HJ, Oh SJ, et al. Nationwide validation study of diagnostic algorithms for inflammatory bowel disease in Korean National Health Insurance Service database. J Gastroenterol Hepatol. 2019; 09. 09. [Epub ahead of print].
Article
20. Kim JW, Lee CK, Rhee SY, Oh CH, Shim JJ, Kim HJ. Trends in health-care costs and utilization for inflammatory bowel disease from 2010 to 2014 in Korea: a nationwide population-based study. J Gastroenterol Hepatol. 2018; 33:847–854.
Article
21. Kim JW, Lee CK, Lee JK, et al. Long-term evolution of direct healthcare costs for inflammatory bowel diseases: a population-based study (2006-2015). Scand J Gastroenterol. 2019; 54:419–426.
Article
22. Ando T, Tsuyuguchi T, Okugawa T, et al. Risk factors for recurrent bile duct stones after endoscopic papillotomy. Gut. 2003; 52:116–121.
Article
23. Lai KH, Lo GH, Lin CK, et al. Do patients with recurrent choledocholithiasis after endoscopic sphincterotomy benefit from regular follow-up? Gastrointest Endosc. 2002; 55:523–526.
Article
24. Boerma D, Rauws EA, Keulemans YC, et al. Wait-and-see policy or laparoscopic cholecystectomy after endoscopic sphincterotomy for bile-duct stones: a randomised trial. Lancet. 2002; 360:761–765.
Article
25. Lau JY, Leow CK, Fung TM, et al. Cholecystectomy or gallbladder in situ after endoscopic sphincterotomy and bile duct stone removal in Chinese patients. Gastroenterology. 2006; 130:96–103.
Article
26. Heo J, Jung MK, Cho CM. Should prophylactic cholecystectomy be performed in patients with concomitant gallstones after endoscopic sphincterotomy for bile duct stones? Surg Endosc. 2015; 29:1574–1579.
Article
27. Lai KH, Lin LF, Lo GH, et al. Does cholecystectomy after endoscopic sphincterotomy prevent the recurrence of biliary complications? Gastrointest Endosc. 1999; 49(4 Pt 1):483–487.
Article
28. Park BK, Seo JH, Jeon HH, et al. A nationwide population-based study of common bile duct stone recurrence after endoscopic stone removal in Korea. J Gastroenterol. 2018; 53:670–678.
Article
29. Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf. 2007; 16:241–249.
Article
30. Lévesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ. 2010; 340:b5087.
Article
31. Dafni U. Landmark analysis at the 25-year landmark point. Circ Cardiovasc Qual Outcomes.
Article